-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) announced that recently, Fosun Carey (Shanghai) Biotechnology Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), initiated phase II clinical trials on FKC516 injection (hereinafter referred to as “FKC516”) for recurrent or refractory B-cell non-Hodgkin lymphoma (r/RB-NHL) in China.

智通财经·11/12/2026 10:17:08
语音播报
Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) announced that recently, Fosun Carey (Shanghai) Biotechnology Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), initiated phase II clinical trials on FKC516 injection (hereinafter referred to as “FKC516”) for recurrent or refractory B-cell non-Hodgkin lymphoma (r/RB-NHL) in China.